Search results
Showing 76 to 90 of 118 results for osteoarthritis
The STAK tool for preventing and treating knee stiffness (MIB252)
NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .
Suture fixation of acute disruption of the distal tibiofibular syndesmosis (HTG374)
Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.
The PediGuard for placing pedicle screws in spinal surgery (MIB26)
NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
Past technology appraisal appeals and decisions
NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)
Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.
Osteoarthritis: the care and management of osteoarthritis in adults (CG59)
This guidance has been updated and replaced by NICE guideline CG177.
LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)
NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
We have moved Medical technologies guidance 76 to become HealthTech guidance 671. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE guideline NG226.
This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671.
Tanezumab for treating pain caused by bone metastases [ID3784]
Discontinued Reference number: GID-TA10922